Bore Da Biotech is a domestic company specializing in raw materials for in vitro diagnostic reagents, researching, developing, and producing antibodies, antigens, and diagnostic reagents.

Since its establishment in 2012 by CEO Dong-Uk Choi, the company has manufactured and supplied various types of antibodies required for diagnosing inflammatory diseases, cancer, and pathogenic microorganisms.

To date, Bore Da Biotech has developed over 4,000 monoclonal antibody cell lines across more than 50 species. The antibodies produced by the company are supplied not only within Korea but also to more than 200 immunodiagnostic reagent manufacturers in the United States, Japan, India, China, and other countries.

As COVID-19 spread worldwide, Bore Da Biotech has focused on developing key raw materials such as antibodies and antigens capable of diagnosing COVID-19.

COVID-19 diagnostic methods are largely divided into molecular diagnostics and immunodiagnostics using antigens and antibodies.

Molecular diagnostic methods detect viral genes, which increases diagnostic accuracy. However, as the number of tests surged with the spread of COVID-19 infections, immunodiagnostic methods such as antigen diagnostic kits that can identify COVID-19 infections quickly have been gaining attention.

Bore Da Biotech develops the core raw materials—antigens and antibodies—used in immunodiagnostic kits and supplies them to domestic diagnostic reagent companies. The company is also establishing a large-scale purification system to ensure stable production.

[Reporter: Park Yun-kyun]